Raymond James hires Chris Raymond as Senior Biotech Research Analyst

ST. PETERSBURG, Fla. – Raymond James has hired Chris Raymond as a managing director and senior analyst on the firm’s biotechnology Equity Research team. Raymond has more than 25 years of sell-side experience covering biotechnology companies. Raymond joins Raymond James from Piper Sandler. Prior to working in equity research, Raymond gained valuable industry insight through various marketing and business development roles at two biopharma companies over 10 years.

“Chris is a strong addition to our talented team of life sciences research analysts,” said Brian Alexander, senior managing director and director of Equity Research. “He has a unique ability to distill and clearly communicate complex subjects in a very dynamic sector. He consistently produces strong fundamental research and has extensive corporate and investor relationships. Our clients will appreciate his intellectual honesty and deep domain expertise.”

Raymond James is heavily investing in the biotech sector and is deeply committed to serving clients in the space. In March, the firm hired Martin Auster, M.D., as a senior research analyst, and with the addition of Raymond, now has five analysts covering the space. The Investment Banking and Sales and Trading teams also continue to make investments in the space, as the entire Capital Markets & Advisory division recognizes the opportunity in this large and dynamic growth industry.

About Raymond James Financial, Inc.

Raymond James Financial, Inc. (NYSE: RJF) is a leading diversified financial services company providing private client group, capital markets, asset management, banking and other services to individuals, corporations and municipalities. Total client assets are $1.58 trillion. Public since 1983, the firm is listed on the New York Stock Exchange under the symbol RJF. Additional information is available at www.raymondjames.com.